Dawn Bell is a seasoned biotech leader with demonstrated success in start-up, specialty and large biopharma. She is currently Senior Global Program Head at Novartis where she leads a cross-functional global team responsible for global registration and commercialization of a multi-billion dollar heart failure asset.
Prior to Novartis, Dawn founded Cool~Bio—a privately held pre-clinical stage company focused on developing a novel hypothermia-activated fusion protein to prevent platelet activation during cardiac surgery. As CEO of Cool~Bio, she negotiated licensing and research development agreements with Emory and Duke University and raised the seed round of funding.
Prior to that, she was Head of the US affiliate of Canyon Pharmaceuticals, a privately held commercial stage biotechnology company, where she developed and executed the business strategy resulting in a US licensing agreement for Iprivask®, a novel anticoagulant. Prior to Canyon, Dawn held various roles of increasing responsibility in market access, medical affairs and clinical development at The Medicines Company.
Dawn earned her Doctor of Pharmacy degree from the University of Florida and completed post-graduate residency training at the University of Illinois at Chicago and a post-graduate fellowship in Cardiovascular Medicine at the University of Florida focusing on the pharmacogenomics of heart failure. Prior to joining industry, Dawn was a tenured associate professor at West Virginia University where she maintained an active research and teaching program in cardiovascular medicine.